Published online Apr 14, 2017. doi: 10.3748/wjg.v23.i14.2592
Peer-review started: November 17, 2016
First decision: December 19, 2016
Revised: January 3, 2017
Accepted: January 18, 2017
Article in press: January 18, 2017
Published online: April 14, 2017
Processing time: 148 Days and 19.2 Hours
To investigate the significance of endothelial progenitor cells (EPCs) in predicting severe acute pancreatitis (SAP).
We recruited 71 patients with acute pancreatitis (AP) and excluded 11 of them; finally, cases of mild acute pancreatitis (MAP) (n = 30) and SAP (n = 30), and healthy volunteers (n = 20) were internalized to investigate levels of EPCs, C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), fibrinogen (FIB) and white blood cells (WBC) in peripheral blood.
The levels of TNF-α, WBC, FIB and CRP were higher both in SAP and MAP cases than in healthy volunteers (P < 0.05, all). Interestingly, the level of EPCs was higher in SAP than MAP (1.63% ± 1.47% vs 6.61% ± 4.28%, P < 0.01), but there was no significant difference between the MAP cases and healthy volunteers (1.63% ± 1.47% vs 0.55% ± 0.54%, P > 0.05). Receiver operating characteristics curve (ROC) showed that EPCs, TNF-α, CRP and FIB were significantly associated with SAP, especially EPCs and CRP were optimal predictive markers of SAP. When the cut-off point for EPCs and CRP were 2.26% and 5.94 mg/dL, the sensitivities were 90.0% and 73.3%, and the specificities were 83.3% and 96.7%. Although, CRP had the highest specificity, and EPCs had the highest sensitivity and highest area under the curve value (0.93).
Data suggest that EPCs may be a new biological marker in predicting SAP.
Core tip: Endothelial progenitor cells (EPCs) may be used as a novel biological marker to predict the severity of acute pancreatitis (AP) considering the relation between endothelial cells and EPCs. We compared five markers, and concluded that EPCs had the highest area under the curve value (0.93) and Youden index (0.8), sensitivity (90.0%) and specificity (83.3%). EPCs may represent a new biological marker for predicting severe AP at the early stage.